Several innovative treatments are reshaping blood sugar care, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide being highlighted promising candidates. Retatrutide, a double GIP and GLP-1 target activator, shows remarkable body mass decrease and better glucose regulation. Cagrillintide, a GLP-1 activator, is currently in research studie